Advertisement

ResearchIn-Press PreviewCardiologyImmunology Open Access | 10.1172/jci.insight.200422

Proteomic profiling of plasma extracellular vesicles reveals a therapeutically targetable liver-heart axis in cardiac transplantation

Shiyu Dai,1 Wei Zhou,1 Fangyu Chen,1 Huanyu Zhang,1 Zhenchun Ji,1 Xuejing Zong,1 Wanruo Zhang,1 Jie Hu,1 Shumin Jiang,1 Fei Wang,1 and Zhenya Shen1

1Institute for Cardiovascular Science and Department of Cardiovascular Surge, Soochow University, Suzhou, China

Find articles by Dai, S. in: PubMed | Google Scholar

1Institute for Cardiovascular Science and Department of Cardiovascular Surge, Soochow University, Suzhou, China

Find articles by Zhou, W. in: PubMed | Google Scholar

1Institute for Cardiovascular Science and Department of Cardiovascular Surge, Soochow University, Suzhou, China

Find articles by Chen, F. in: PubMed | Google Scholar

1Institute for Cardiovascular Science and Department of Cardiovascular Surge, Soochow University, Suzhou, China

Find articles by Zhang, H. in: PubMed | Google Scholar

1Institute for Cardiovascular Science and Department of Cardiovascular Surge, Soochow University, Suzhou, China

Find articles by Ji, Z. in: PubMed | Google Scholar

1Institute for Cardiovascular Science and Department of Cardiovascular Surge, Soochow University, Suzhou, China

Find articles by Zong, X. in: PubMed | Google Scholar

1Institute for Cardiovascular Science and Department of Cardiovascular Surge, Soochow University, Suzhou, China

Find articles by Zhang, W. in: PubMed | Google Scholar

1Institute for Cardiovascular Science and Department of Cardiovascular Surge, Soochow University, Suzhou, China

Find articles by Hu, J. in: PubMed | Google Scholar

1Institute for Cardiovascular Science and Department of Cardiovascular Surge, Soochow University, Suzhou, China

Find articles by Jiang, S. in: PubMed | Google Scholar

1Institute for Cardiovascular Science and Department of Cardiovascular Surge, Soochow University, Suzhou, China

Find articles by Wang, F. in: PubMed | Google Scholar

1Institute for Cardiovascular Science and Department of Cardiovascular Surge, Soochow University, Suzhou, China

Find articles by Shen, Z. in: PubMed | Google Scholar

Published July 2, 2026 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.200422.
Copyright © 2026, Dai et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published July 2, 2026 - Version history
View PDF
Abstract

Extracellular vesicles (EVs)-mediated inter-organ communication represents a promising frontier in transplant immunology; however, its role in cardiac allograft rejection remains poorly characterized. We performed proteomic profiling of plasma-derived EVs in a rat heterotopic heart transplantation model and identified a distinct liver-predominant protein signature during acute rejection, with Antithrombin III (ATIII) emerging as a top candidate. Functional validation revealed that pharmacological EV inhibition intensified systemic and intragraft inflammation, whereas adeno-associated virus (AAV)-mediated silencing of hepatic ATIII directly accelerated allograft rejection. Conversely, AAV-mediated hepatocyte-specific ATIII overexpression attenuated rejection pathology, reduced immune cell recruitment, and markedly prolonged median graft survival. This protective effect was achieved without evidence of coagulopathic complications, indicating an immunomodulatory mechanism beyond ATIII’s canonical anticoagulant function. Mechanistically, ATIII overexpression was associated with upregulation of heme oxygenase-1 (HO-1) in the liver and suppression of proinflammatory cytokine expression in the graft. These findings highlight hepatocyte-derived EVs as important mediators of a liver-heart signaling axis in transplant rejection, and further implicate the protein ATIII as a contributor to this axis. Our study reveals a therapeutically targetable liver-heart signaling axis in transplant rejection, whereby enhancing liver-derived ATIII or its downstream pathways (such as HO-1) could attenuate acute cardiac allograft rejection.

Graphical Abstract
graphical abstract
Supplemental material

View

View Unedited blot and gel images

Version history
  • Version 1 (July 2, 2026): In-Press Preview
Advertisement
Advertisement